PPARG and diabetic kidney disease: Recent studies have suggested that peroxisome proliferator-activated receptor-γ  (PPARγ) synthetic agonist thiazolidinediones, such as rosiglitazone, may prevent or attenuate diabetic nephropathy in animal models [6, 7].